Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit

By Jonathan Capriel · March 14, 2022, 9:01 PM EDT

A Kansas federal court has preliminarily approved a $264 million deal that would end claims that Mylan colluded with Pfizer Inc. to obstruct generic versions of the EpiPen, the emergency drug...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By Jonathan

November 14, 2024
NY Nursing Homes Ink $45M Deal To End AG's Fraud Suit
October 16, 2024
SEC To Settle Claims CBD Exec Took $13M From Hospital
October 15, 2024
Conn. Medical Group Hit With $30M Verdict In C-Section Suit
September 04, 2024
Albertsons Denied Texas Court Remand In Opioid MDL
May 29, 2024
5th Circ. Sends Hain Toxic Baby Food Suit To State Court
May 02, 2024
Biden Announces $3B To Fund Lead Pipe Replacement
April 30, 2024
BCBS Says Federal Drug Law Preempts NM Medical Weed Row
April 24, 2024
Pa. Court Revives Malpractice Suit Over Hip Implant Surgeries
April 16, 2024
Amazon Beats Suit After Injured Drivers Bury Medical Details
April 05, 2024
Mo. High Court Affirms Co.'s Medical Pot License Denial